Dr. Rosenfeld received both his MD and PhD degrees from the Johns Hopkins School of Medicine, and he completed a research fellowship and residency in Ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard Medical School. Following his residency, Dr. Rosenfeld completed a Vitreoretinal fellowship at the Bascom Palmer Eye Institute, University of Miami Miller School of Medicine. In 1996, he joined the faculty of the Bascom Palmer Eye Institute where he is now an associate professor of Ophthalmology. Dr. Rosenfeld is a member of the American Academy of Ophthalmology (AAO), the American Society of Retinal Specialists (ASRS), the Retina Society, the Macula Society, and the Association for Research in Vision and Ophthalmology (ARVO).
Dr. Rosenfeld specializes in medical and surgical diseases of the retina with a primary research interest in age-related macular degeneration. Since joining the faculty at the Bascom Palmer Eye Institute, Dr. Rosenfeld has been a principal investigator in several photodynamic therapy trials using verteporfin, as well as the Lucentis (Genentech) Phase I/II/III trials, the Macugen (pegaptanib, Eyetech) Phase II/III trials, and the Anecortave Acetate (RETAANE, Alcon) Phase II/III clinical trials. He is currently involved in additional clinical trials investigating other anti-angiogenic therapies for neovascular AMD including systemic bevacizumab (Avastin). He pioneered the use of intravitreal Avastin for the treatment of neovascular AMD and macular edema.